Last updated: September 8, 2026
Follistim, the recombinant follicle-stimulating hormone follitropin beta, remains a commercially established fertility product but is a mature asset rather than a growth driver. Organon owns the U.S. commercial rights after acquiring Merck’s women’s health, biosimilars, and established-brand businesses in 2021. Product-level revenue is not publicly disclosed. Follistim’s outlook depends on assisted reproductive technology demand, pricing, supply reliability, competition from Gonal-f and urinary gonadotropins, and the pace of biosimilar or interchangeable recombinant FSH development.
The core biologic patent estate is mature. The main commercial barriers are now regulatory complexity, manufacturing know-how, product-specific clinical requirements, device compatibility, physician familiarity, and payer contracting rather than a clearly identified, active composition-of-matter patent blocking U.S. competition.
What is Follistim and how is it used?
Follistim is recombinant human follicle-stimulating hormone, or follitropin beta. It is manufactured using recombinant DNA technology in a mammalian cell system and is administered by subcutaneous injection.
The U.S. Food and Drug Administration approved Follistim for two principal uses:
| Use |
Patient population |
Commercial role |
| Ovulation induction |
Anovulatory women, including women with polycystic ovary syndrome |
Treatment before timed intercourse or intrauterine insemination |
| Controlled ovarian stimulation |
Women undergoing assisted reproductive technology, including in vitro fertilization |
Stimulation of multiple ovarian follicles before oocyte retrieval |
Follistim AQ is supplied in cartridges in 300 IU, 600 IU, and 900 IU strengths for use with the Follistim Pen. The pen-and-cartridge system is a central commercial differentiator because fertility treatment requires repeated, dose-adjusted administration over a stimulation cycle. [1]
Treatment is typically managed by reproductive endocrinologists and specialized fertility clinics. The product is not an oral therapy and is administered in a high-touch, protocol-driven market where clinical familiarity and clinic purchasing relationships influence product selection.
Who owns Follistim and which companies commercialize competing products?
Organon markets Follistim in the United States. Merck & Co. transferred the relevant established-brand and women’s health commercial assets to Organon as part of the 2021 separation and related transaction. [2]
The principal competitive products are:
| Product |
Active ingredient |
Company or commercial sponsor |
Product type |
| Follistim AQ |
Follitropin beta |
Organon |
Recombinant FSH |
| Gonal-f |
Follitropin alfa |
EMD Serono, part of Merck KGaA |
Recombinant FSH |
| Menopur |
Menotropins, urinary-derived gonadotropins |
Ferring Pharmaceuticals |
Human menopausal gonadotropin |
| Bravelle |
Urofollitropin |
Ferring Pharmaceuticals |
Urinary-derived FSH; U.S. commercial status has changed over time |
| Rekovelle |
Follitropin delta |
Ferring Pharmaceuticals |
Recombinant FSH, marketed in selected non-U.S. markets |
Gonal-f is Follistim’s closest branded competitor. Both are recombinant FSH products used in ovarian stimulation and ovulation induction. Menopur competes for the same treatment cycles but contains both FSH and luteinizing-hormone activity.
How large is the Follistim and fertility-drug market?
Follistim participates in the broader gonadotropin and fertility pharmaceutical market rather than a standalone therapeutic market reported by financial exchanges.
Demand is supported by several structural factors:
- Increasing use of IVF and intracytoplasmic sperm injection.
- Later maternal age and declining fecundity.
- Growth of fertility clinic networks.
- Greater insurance coverage for infertility treatment in selected U.S. states.
- Rising use of fertility preservation and elective oocyte cryopreservation.
- Increased public and employer-sponsored fertility benefits.
The Centers for Disease Control and Prevention reports more than 400,000 assisted reproductive technology cycles annually in the United States in recent reporting years, although cycles vary by year and reporting methodology. [3] Follistim is used in a portion of these cycles, but the product’s unit demand cannot be derived directly from cycle counts because protocols differ in dose, duration, and use of adjunctive gonadotropins.
The market is geographically concentrated in developed fertility markets, including the United States, Western Europe, Japan, Australia, and selected Middle Eastern markets. The U.S. is commercially important because treatment prices, clinic consolidation, and private-pay spending support higher product value than many public reimbursement systems.
What is the financial trajectory of Follistim?
Follistim product revenue is not separately disclosed in Organon’s public financial reporting. Organon reports revenue by broader operating categories and product groups, not by individual fertility brand. The absence of a separate revenue line prevents a precise public calculation of Follistim sales, market share, gross margin, or annual growth.
Organon’s financial profile gives several indications about the product’s role:
- Follistim belongs to the established brands and women’s health portfolio.
- The product contributes recurring revenue from treatment cycles rather than one-time purchases.
- It is unlikely to be a major consolidated growth engine because Organon’s reported growth priorities include newer medicines, biosimilars, and broader portfolio expansion.
- Its mature manufacturing base can support attractive cash generation if pricing and volume remain stable.
- Revenue is exposed to fertility-cycle volumes, reimbursement policy, clinic purchasing concentration, and competitive contracting.
Organon reported approximately $6.4 billion in total revenue for 2023 and approximately $6.4 billion for 2024, with portfolio-level reporting that does not isolate Follistim. [4,5] The company’s women’s health and established-brands businesses provide the relevant financial context, but Follistim-specific trajectory must be assessed through market share, prescription, tender, and channel data rather than company-reported sales.
Follistim revenue scenarios
| Scenario |
Market condition |
Expected effect on Follistim |
| Base case |
Stable IVF demand, no major U.S. biosimilar, modest pricing pressure |
Low-single-digit nominal stability or gradual decline |
| Upside case |
Higher IVF volumes, expanded insurance coverage, improved clinic access, stable supply |
Volume growth with limited price erosion |
| Downside case |
Recombinant FSH biosimilar entry, aggressive Gonal-f contracting, reimbursement pressure |
Price erosion and share loss |
| Severe downside case |
Multiple interchangeable products and concentrated clinic tenders |
Rapid price compression and reduced formulary access |
The most likely financial profile is mature and cash-generative, with limited organic growth and a greater risk of gradual erosion than abrupt loss of exclusivity.
When does Follistim lose exclusivity?
Follistim’s original product and manufacturing patents are mature. The original recombinant FSH patent families were filed in the 1980s and early 1990s, placing the core patent protection well before the current commercial period under ordinary U.S. patent terms.
The principal U.S. market protection is therefore no longer based on an unexpired foundational composition patent. Any remaining protection would more likely involve:
- Cartridge and injector-device configurations.
- Manufacturing processes.
- Cell lines and purification methods.
- Stability and formulation claims.
- Packaging or dose-delivery systems.
- Regulatory exclusivity associated with the reference biologic.
A precise, current patent-expiration date for every Follistim-related patent cannot be inferred from the product label alone. Patent status must be evaluated by patent family, claim scope, terminal disclaimers, maintenance fees, and whether a claim covers the marketed product rather than an unrelated production process.
What is the FDA regulatory status of Follistim?
Follistim is an FDA-approved biologic. The product is regulated under the Public Health Service Act and is subject to biologic manufacturing, quality, potency, sterility, and supply controls.
Key regulatory characteristics include:
| Regulatory issue |
Follistim position |
| FDA status |
Approved biologic |
| Active ingredient |
Follitropin beta |
| Administration |
Subcutaneous injection |
| Delivery system |
Follistim Pen with cartridge |
| Main indications |
Ovulation induction and assisted reproductive technology |
| Reference-product pathway |
Biologic reference product |
| Primary competition pathway |
Section 351(k) biosimilar or interchangeable biologic pathway |
Follistim was approved before the modern biosimilar pathway was implemented. Under the Biologics Price Competition and Innovation Act, a later sponsor could seek approval through an abbreviated 351(k) application if it demonstrates biosimilarity and, where applicable, interchangeability. [6]
What is the Orange Book and Purple Book status of Follistim?
Follistim is a biologic, so the Purple Book is more relevant than the Orange Book for reference-product and biosimilar information. The Orange Book primarily covers small-molecule drugs approved under the Federal Food, Drug, and Cosmetic Act.
The principal legal questions are:
- Whether the reference product is listed in the Purple Book.
- Whether Organon or another rights holder has submitted patent information under the applicable biologic framework.
- Whether a biosimilar applicant has initiated the statutory patent-exchange process.
- Whether any device or drug-delivery patents are asserted separately.
No widely reported U.S. Paragraph IV litigation has established a current generic challenge to Follistim comparable to a small-molecule Hatch-Waxman dispute. A biosimilar applicant would generally proceed through the 351(k) pathway rather than file a conventional abbreviated new drug application with a Paragraph IV certification.
Which companies are challenging Follistim?
The principal competitive threat is commercial substitution, not publicly established patent litigation.
Gonal-f is the closest branded challenger. It has the same broad therapeutic role but contains follitropin alfa rather than follitropin beta. Because both products are recombinant FSH products, fertility clinics can compare dose-response, ovarian response, handling, supply, and payer terms.
Menopur competes through a different biological profile. It supplies FSH activity with LH activity and is used in stimulation protocols where clinicians want that combination.
Potential future challengers include:
- Biosimilar follitropin beta products.
- Biosimilar follitropin alfa products.
- New recombinant FSH products with longer half-life or individualized dosing.
- Lower-cost urinary-derived gonadotropins.
- Digital dosing and monitoring systems that influence product selection.
As of the latest broadly available public regulatory information, there is no established U.S. biosimilar launch that has materially displaced Follistim in the U.S. market. The absence of a launched biosimilar does not mean the asset has indefinite protection. It indicates that development, manufacturing, clinical comparability, and commercial return have not yet produced a visible U.S. entrant.
How strong is the Follistim patent estate?
Follistim has a moderate commercial protection profile but a weak foundation for long-term exclusivity based solely on original patents.
| Protection category |
Assessment |
| Core recombinant FSH patents |
Mature or expired in the principal commercial period |
| Product-specific formulation |
Potentially relevant, but not clearly sufficient to block all biosimilar entry |
| Pen and cartridge patents |
Can increase substitution friction but may not block a different delivery system |
| Manufacturing know-how |
Material practical barrier, especially for glycosylated biologics |
| Regulatory data and approval history |
Meaningful development advantage for the reference product |
| Brand and clinic familiarity |
Important commercial protection |
| Biosimilar litigation exposure |
Possible, but no established major U.S. dispute is evident from public reporting |
Manufacturing know-how may be more important than patent term. Follitropin beta is a glycoprotein whose activity can be affected by cell-line characteristics, glycosylation, purification, aggregate control, potency assays, and stability. A competitor must produce a highly comparable product and satisfy regulators that differences do not create clinically meaningful effects.
The pen is also commercially relevant. A biosimilar could avoid direct infringement by using a different injector, but that would require patient and clinic adoption and could weaken the convenience advantage associated with the established delivery system.
What generic or biosimilar launch risks exist?
The main risk is a delayed but potentially material biosimilar entry rather than immediate generic substitution.
Near-term risk
Near-term U.S. risk is moderate. Follistim is mature, but recombinant gonadotropin development requires specialized analytical and clinical capabilities. The product’s market is smaller than markets for insulin, monoclonal antibodies, or high-volume hospital biologics, which can reduce the commercial incentive for multiple entrants.
Medium-term risk
Medium-term risk is higher if a sponsor can:
- Demonstrate analytical similarity with a limited clinical program.
- Use a lower-cost pen or prefilled delivery format.
- Obtain preferred payer status.
- Secure contracts with national fertility clinic networks.
- Offer a product with reliable supply and competitive reimbursement.
Launch sequence
A likely U.S. entry sequence would be:
- FDA 351(k) filing.
- Patent and regulatory exclusivity review.
- Patent litigation or negotiated resolution, if applicable.
- Approval with product-specific labeling.
- Initial launch through fertility-clinic and specialty-pharmacy channels.
- Payer and clinic contracting.
- Gradual substitution, subject to state pharmacy laws and prescriber behavior.
Automatic pharmacy substitution would depend on an FDA interchangeability designation and applicable state law. Without interchangeability, a biosimilar could still compete through physician prescribing and payer incentives, but substitution would be less automatic.
What patent litigation and settlement agreements affect Follistim?
No major, publicly established U.S. patent settlement involving a Follistim biosimilar challenger has defined the current market structure in the manner seen for several high-revenue biologics.
The relevant litigation risk is more likely to arise from:
- Patent claims covering a specific injector or cartridge.
- Manufacturing-process patents.
- Patent infringement claims filed after a 351(k) application.
- Trade-secret or confidential manufacturing disputes.
- Contract claims involving distributors, fertility networks, or licensing partners.
Patent settlements could delay a biosimilar launch, permit an agreed future entry date, or allow entry with a non-infringing device. Because no major public settlement currently anchors the market, launch timing should be modeled around regulatory and commercial execution rather than a known negotiated date.
What licensing deals determine Follistim’s commercial position?
The principal strategic transaction was Organon’s acquisition of Merck’s established brands, women’s health, and biosimilars businesses in 2021. Follistim was part of the transferred commercial portfolio. [2]
The transaction gave Organon control of the commercial platform, product supply relationships, and established-market infrastructure associated with Follistim. It did not create a new exclusivity period for the active ingredient.
Potential value in the asset is therefore tied to:
- Commercial rights by territory.
- Manufacturing and supply agreements.
- Device technology.
- Distribution arrangements.
- Clinic-network contracts.
- Regulatory ownership and lifecycle management.
The transaction also placed Follistim in a portfolio company whose strategy emphasizes cash generation from established brands while investing selectively in growth assets.
How does Follistim compare with Gonal-f?
| Factor |
Follistim |
Gonal-f |
| Active ingredient |
Follitropin beta |
Follitropin alfa |
| Biological class |
Recombinant FSH |
Recombinant FSH |
| Primary use |
Ovulation induction and ART |
Ovulation induction and ART |
| Main U.S. sponsor |
Organon |
EMD Serono |
| Delivery |
Pen and cartridge |
Pen-based delivery and other presentations depending on market |
| Competitive basis |
Clinical familiarity, device, supply, contracting |
Clinical familiarity, device, supply, contracting |
| Patent posture |
Mature core estate |
Mature core estate |
| Main threat |
Gonal-f, Menopur, future biosimilar |
Follistim, Menopur, future biosimilar |
Neither product has an obvious universal clinical advantage across all patients. Product choice often depends on physician preference, protocol design, local reimbursement, clinic purchasing, and availability.
What are Follistim’s geographic growth opportunities?
The strongest opportunities are in markets where fertility treatment is expanding and private or mixed reimbursement supports gonadotropin use.
United States
The U.S. offers the highest commercial value but also has intense branded competition, payer scrutiny, and clinic consolidation. Expanded employer benefits and state insurance mandates can increase treatment volumes, although coverage varies significantly.
Europe
European markets have substantial IVF activity but more direct price regulation and tendering. National reimbursement systems can reduce net pricing and increase the importance of procurement contracts.
Asia-Pacific
Japan, Australia, and selected Asian markets have established ART infrastructure. China and other developing markets offer volume potential but may involve local pricing controls, registration requirements, and domestic competition.
Middle East and Latin America
Private fertility services can support demand, but market access is sensitive to distributor structure, currency, reimbursement, and local regulatory requirements.
What is the investment view on Follistim?
Follistim should be analyzed as a mature specialty biologic with durable but limited growth potential.
| Investment factor |
Current implication |
| Demand |
Structurally supported by ART growth |
| Pricing |
Vulnerable to payer and clinic negotiation |
| Competition |
Strong branded competition; future biosimilar risk |
| Patent protection |
Limited reliance on core composition patents |
| Manufacturing |
Meaningful barrier because of glycoprotein complexity |
| Revenue disclosure |
Product sales not separately reported |
| Margin profile |
Potentially attractive if supply and pricing remain stable |
| Growth profile |
More likely stable or declining than high growth |
| Litigation |
No major public dispute currently defining market access |
| Strategic value |
Recurring revenue and fertility-market presence |
The financial trajectory depends more on market share preservation than on patent-led price protection. Organon can defend the product through device convenience, manufacturing consistency, supply reliability, physician familiarity, and contracting. Those advantages may delay erosion, but they are less durable than a valid blocking patent.
Key Takeaways
- Follistim is recombinant follitropin beta used for ovulation induction and assisted reproductive technology.
- Organon owns the U.S. commercial rights following its 2021 acquisition of Merck’s established brands and women’s health assets.
- Follistim revenue is not separately disclosed, so product-level growth and market share cannot be calculated from public financial statements.
- The product is a mature biologic with core patent protection largely historical rather than a clear long-term exclusivity barrier.
- Gonal-f is the closest branded competitor; Menopur competes through a different gonadotropin composition.
- The principal future threat is a 351(k) biosimilar, although no major U.S. biosimilar launch has publicly displaced Follistim.
- Manufacturing complexity, pen-and-cartridge design, clinic relationships, supply reliability, and payer contracts are the key practical defenses.
- Base-case performance is stable to modestly declining revenue, with downside risk increasing if an interchangeable biosimilar gains preferred payer and clinic access.
- No major publicly established Paragraph IV dispute or Follistim biosimilar settlement currently sets a definitive U.S. entry date.
FAQs
Is Follistim a biologic or a small-molecule drug?
Follistim is a recombinant biologic containing follitropin beta, a glycoprotein hormone. Biosimilar competition would generally proceed under the FDA’s 351(k) pathway rather than through a conventional small-molecule ANDA.
Is Follistim interchangeable with Gonal-f?
No. Follistim and Gonal-f contain different recombinant FSH molecules, follitropin beta and follitropin alfa. Treatment decisions remain subject to the prescribing clinician, protocol, payer policy, and product availability.
Does Follistim have an active composition-of-matter patent?
The foundational recombinant FSH patent families are mature. Current commercial protection is more likely to involve device, formulation, manufacturing, or regulatory factors than a broad active composition patent.
Could a biosimilar automatically substitute for Follistim at the pharmacy?
Only if the FDA grants interchangeability and the applicable state pharmacy law permits substitution. A biosimilar without interchangeability could still compete through physician prescribing, payer preference, and clinic contracts.
Why is Follistim financially important if Organon does not report its sales separately?
Follistim provides recurring specialty-pharmacy and fertility-clinic revenue within Organon’s broader established-brands and women’s health portfolio. Its strategic value is portfolio cash flow and market presence, not disclosed standalone revenue growth.
References
- U.S. Food and Drug Administration. (2023). Follistim AQ prescribing information. FDA.
- Organon & Co. (2021). Organon completes acquisition of Merck’s women’s health, biosimilars, and established brands businesses. Organon.
- Centers for Disease Control and Prevention. (2024). Assisted reproductive technology: Fertility clinic and national summary report. U.S. Department of Health and Human Services.
- Organon & Co. (2024). 2023 annual report. Organon.
- Organon & Co. (2025). 2024 annual report. Organon.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. FDA.
